Total Artificial Heart - Medical Devices Pipeline Assessment, 2018 - Product Image

Total Artificial Heart - Medical Devices Pipeline Assessment, 2018

  • ID: 4544599
  • Report
  • 64 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart Inc
  • Foster-Miller Inc
  • OregonHeart Inc
  • MORE
Total Artificial Heart - Medical Devices Pipeline Assessment, 2018

Summary

The author's Medical Devices sector report, “Total Artificial Heart - Medical Devices Pipeline Assessment, 2018" provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry.
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart Inc
  • Foster-Miller Inc
  • OregonHeart Inc
  • MORE
1 Table of Contents

2 Introduction
2.1 Total Artificial Heart Overview

3 Products under Development
3.1 Total Artificial Heart - Pipeline Products by Stage of Development
3.2 Total Artificial Heart - Pipeline Products by Territory
3.3 Total Artificial Heart - Pipeline Products by Regulatory Path
3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date
3.5 Total Artificial Heart - Ongoing Clinical Trials

4 Total Artificial Heart - Pipeline Products under Development by Companies
4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development
4.2 Total Artificial Heart - Pipeline Products by Stage of Development

5 Total Artificial Heart Companies and Product Overview
5.1 Abiomed Inc Company Overview
5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 BiVacor Pty Ltd Company Overview
5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.3 Carmat SAS Company Overview
5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
5.4 Cleveland Heart Inc Company Overview
5.4.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Foster-Miller Inc (Inactive) Company Overview
5.5.1 Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.6 Indian Institute of Technology Kharagpur Company Overview
5.6.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
5.7 OregonHeart Inc (Inactive) Company Overview
5.7.1 OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.8 ReliantHeart, Inc. Company Overview
5.8.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.9 Scandinavian Real Heart AB Company Overview
5.9.1 Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
5.10 Syncardia Systems LLC Company Overview
5.10.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
5.11 TEDA International Cardiovascular Hospital Company Overview
5.11.1 TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
5.12 University of Tokyo Company Overview
5.12.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview

6 Total Artificial Heart- Recent Developments
6.1 May 17, 2018: Artificial heart technology gets federal funding
6.2 May 15, 2018: Micron Solutions Reports 2018 First Quarter Results
6.3 May 14, 2018: Real Heart: Continued progress in the second preclinical trial
6.4 May 03, 2018: Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year
6.5 Apr 05, 2018: CARMAT: Continuing Progress in Line with the Objective of Obtaining CE Marking in 2019
6.6 Mar 30, 2018: Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
6.7 Mar 26, 2018: Micron Solutions Reports 2017 Fourth Quarter and Year End Results
6.8 Feb 27, 2018: Scandinavian Real Heart Selects AdaCore Embedded Software Development Platform for Revolutionary Artificial Heart
6.9 Feb 20, 2018: CARMAT Advances the Internationalization of the PIVOTAL Study and Obtains the Approval to Perform Implants in Denmark
6.10 Feb 13, 2018: Carmat: 2017 Annual Results
6.11 Feb 01, 2018: Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
6.12 Jan 08, 2018: Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154M, Up 34% Over Prior Year
6.13 Dec 08, 2017: Micron Solutions Designates Mr. E. P. Marinos as a Director Emeritus and Appoints Mr. Andrei Soran to its Board of Directors
6.14 Nov 27, 2017: First Implantation in the Czech Republic within the Framework of the PIVOTAL Study International Expansion
6.15 Nov 13, 2017: Micron Solutions Reports 2017 Third Quarter Results
6.16 Oct 30, 2017: CARMAT accelerates the internationalization of the PIVOTAL study and obtains the approval to perform implants in the Czech Republic
6.17 Oct 26, 2017: Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
6.18 Oct 23, 2017: International implant of the CARMAT heart
6.19 Oct 19, 2017: Abiomed's Impella Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
6.20 Oct 05, 2017: CARMAT expands its PIVOTAL study internationally, in line with its clinical strategy and CE marking process
6.21 Sep 29, 2017: Scandinavian Real Heart Announces the Progress in Total Artificial Heart
6.22 Sep 29, 2017: Scandinavian Real Heart: Progress in Real Heart’s Product Development
6.23 Sep 26, 2017: CARMAT: 2017 Half-Year Results
6.24 Sep 01, 2017: CARMAT appoints Francesco Arecchi, previously Product Manager EMEA Structural Heart at Abbott, as Marketing Manager
6.25 Aug 28, 2017: Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant
6.26 Aug 11, 2017: Micron Solutions Reports 2017 Second Quarter Results
6.27 Jul 27, 2017: Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
6.28 Jul 24, 2017: Micron Solutions Appoints Rodd E. Friedman to its Board of Directors
6.29 Jul 06, 2017: CARMAT Appoints Wenzel Hurtak, Previously Business Director New Products at Contract Medical International GmbH, as Director of Manufacturing
6.30 Jul 03, 2017: Real Heart plans to perform next series of tests in the United States
6.31 Jul 03, 2017: Real Heart plans to perform next series of tests in the United States
6.32 Jun 21, 2017: Italian Boy Becomes Youngest Patient Bridged to Transplant with the SynCardia temporary Total Artificial Heart

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Total Artificial Heart - Pipeline Products by Stage of Development
Table 2: Total Artificial Heart - Pipeline Products by Territory
Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Table 5: Total Artificial Heart - Ongoing Clinical Trials
Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development
Table 7: Total Artificial Heart - Pipeline Products by Stage of Development
Table 8: Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: AbioCor II - Product Status
Table 10: AbioCor II - Product Description
Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 12: BiVACOR Device - Product Status
Table 13: BiVACOR Device - Product Description
Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Artificial Heart - Product Status
Table 16: Artificial Heart - Product Description
Table 17: Carmat SAS - Ongoing Clinical Trials Overview
Table 18: Artificial Heart - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure
Table 19: Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 20: SmartHeart TAH - Product Status
Table 21: SmartHeart TAH - Product Description
Table 22: Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 23: MagScrew Total Artificial Heart - Product Status
Table 24: MagScrew Total Artificial Heart - Product Description
Table 25: Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Artificial Heart - Product Status
Table 27: Artificial Heart - Product Description
Table 28: OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Next Generation Total Artificial Heart - Product Status
Table 30: Next Generation Total Artificial Heart - Product Description
Table 31: ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Pulse Less Total Artificial Heart - Product Status
Table 33: Pulse Less Total Artificial Heart - Product Description
Table 34: Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Total Artificial Heart - Product Status
Table 36: Total Artificial Heart - Product Description
Table 37: Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 38: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Status
Table 39: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Description
Table 40: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 41: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 42: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Status
Table 43: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Description
Table 44: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 45: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 46: Syncardia Systems LLC - Ongoing Clinical Trials Overview
Table 47: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
Table 48: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
Table 49: TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Artificial Heart - Product Status
Table 51: Artificial Heart - Product Description
Table 52: University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Helical Flow Total Artificial Heart - Product Status
Table 54: Helical Flow Total Artificial Heart - Product Description
Table 55: Glossary

List of Figures
Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
Figure 2: Total Artificial Heart - Pipeline Products by Territory
Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Figure 5: Total Artificial Heart - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart Inc
  • Foster-Miller Inc
  • Indian Institute of Technology Kharagpur
  • OregonHeart Inc
  • ReliantHeart Inc.
  • Scandinavian Real Heart AB
  • Syncardia Systems LLC
  • TEDA International Cardiovascular Hospital
  • University of Tokyo
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll